Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
4
PIII Quote, Financials, Valuation and Earnings
Last price:
$0.19
Seasonality move
:
-30.67%
Day range:
$0.18 - $0.21
52-week range:
$0.18 - $1.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.26x
Volume:
382.9K
Avg. volume:
635.7K
1-year change:
-83.62%
Market cap:
$30.9M
Revenue:
$1.3B
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
$358.1M | -- | 9.23% | -- | -- |
|
AMS
American Shared Hospital Services
|
$7.5M | $0.08 | 35.14% | -83.33% | -- |
|
ASTH
Astrana Health
|
$462.4M | $0.38 | 73.22% | -65.39% | $64.5000 |
|
BTMD
Biote
|
$51.4M | $0.20 | 12.23% | -5.56% | -- |
|
CCEL
Cryo-Cell International
|
$8M | $0.02 | 1.41% | -63.47% | $9.00 |
|
OMCL
Omnicell
|
$280.5M | $0.42 | 15.08% | 249.27% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
$0.19 | -- | $30.9M | -- | $0.00 | 0% | 0.02x |
|
AMS
American Shared Hospital Services
|
$3.32 | -- | $21.3M | 5.53x | $0.00 | 0% | 0.87x |
|
ASTH
Astrana Health
|
$33.7000 | $64.5000 | $1.5B | 25.92x | $0.00 | 0% | 0.93x |
|
BTMD
Biote
|
$6.11 | -- | $190.1M | 23.50x | $0.00 | 0% | 1.06x |
|
CCEL
Cryo-Cell International
|
$7.83 | $9.00 | $63.1M | -- | $0.25 | 3.19% | 2.03x |
|
OMCL
Omnicell
|
$44.98 | -- | $2.1B | -- | $0.00 | 0% | 1.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PIII
P3 Health Partners
|
52.54% | 1.972 | 64.79% | 0.47x |
|
AMS
American Shared Hospital Services
|
45.9% | -0.001 | 90.05% | 1.35x |
|
ASTH
Astrana Health
|
38.34% | 1.507 | 17.07% | 1.84x |
|
BTMD
Biote
|
-1029.09% | 4.522 | 67.07% | 1.01x |
|
CCEL
Cryo-Cell International
|
634.51% | -0.093 | 19.24% | 0.43x |
|
OMCL
Omnicell
|
31.72% | 0.182 | 28.33% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
-- | -$107M | -20.12% | -26.35% | -27.84% | -$22.6M |
|
AMS
American Shared Hospital Services
|
$1.4M | -$553K | 8.36% | 13.75% | -3.47% | -$407K |
|
ASTH
Astrana Health
|
$73.5M | $28.4M | 7.4% | 12.67% | 7.45% | $31.7M |
|
BTMD
Biote
|
$36.2M | $12.2M | 28.47% | -- | 37.75% | $13.6M |
|
CCEL
Cryo-Cell International
|
$6M | $1.7M | -212.19% | -- | 22.4% | -$911.8K |
|
OMCL
Omnicell
|
$122.3M | $6.6M | -1% | -1.47% | 2.32% | $9.4M |
P3 Health Partners vs. Competitors
-
Which has Higher Returns PIII or AMS?
American Shared Hospital Services has a net margin of -12.84% compared to P3 Health Partners's net margin of -2.96%. P3 Health Partners's return on equity of -26.35% beat American Shared Hospital Services's return on equity of 13.75%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M AMSAmerican Shared Hospital Services19.57% -$0.03 $54.2M -
What do Analysts Say About PIII or AMS?
P3 Health Partners has a consensus price target of --, signalling upside risk potential of 228.95%. On the other hand American Shared Hospital Services has an analysts' consensus of -- which suggests that it could grow by 35.54%. Given that P3 Health Partners has higher upside potential than American Shared Hospital Services, analysts believe P3 Health Partners is more attractive than American Shared Hospital Services.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners0 0 0 AMSAmerican Shared Hospital Services0 0 0 -
Is PIII or AMS More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.72%.
-
Which is a Better Dividend Stock PIII or AMS?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or AMS?
P3 Health Partners quarterly revenues are $362.1M, which are larger than American Shared Hospital Services quarterly revenues of $7M. P3 Health Partners's net income of -$46.5M is lower than American Shared Hospital Services's net income of -$207K. Notably, P3 Health Partners's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 5.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.87x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.02x -- $362.1M -$46.5M AMSAmerican Shared Hospital Services0.87x 5.53x $7M -$207K
-
Which has Higher Returns PIII or ASTH?
Astrana Health has a net margin of -12.84% compared to P3 Health Partners's net margin of 3.36%. P3 Health Partners's return on equity of -26.35% beat Astrana Health's return on equity of 12.67%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M ASTHAstrana Health15.35% $0.33 $945.2M -
What do Analysts Say About PIII or ASTH?
P3 Health Partners has a consensus price target of --, signalling upside risk potential of 228.95%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 91.4%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners0 0 0 ASTHAstrana Health10 2 0 -
Is PIII or ASTH More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock PIII or ASTH?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or ASTH?
P3 Health Partners quarterly revenues are $362.1M, which are smaller than Astrana Health quarterly revenues of $478.7M. P3 Health Partners's net income of -$46.5M is lower than Astrana Health's net income of $16.1M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.02x -- $362.1M -$46.5M ASTHAstrana Health0.93x 25.92x $478.7M $16.1M
-
Which has Higher Returns PIII or BTMD?
Biote has a net margin of -12.84% compared to P3 Health Partners's net margin of 20.83%. P3 Health Partners's return on equity of -26.35% beat Biote's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M BTMDBiote70.47% $0.33 -$8M -
What do Analysts Say About PIII or BTMD?
P3 Health Partners has a consensus price target of --, signalling upside risk potential of 228.95%. On the other hand Biote has an analysts' consensus of -- which suggests that it could grow by 62.79%. Given that P3 Health Partners has higher upside potential than Biote, analysts believe P3 Health Partners is more attractive than Biote.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners0 0 0 BTMDBiote0 0 0 -
Is PIII or BTMD More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PIII or BTMD?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or BTMD?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Biote quarterly revenues of $51.4M. P3 Health Partners's net income of -$46.5M is lower than Biote's net income of $10.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Biote's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.06x for Biote. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.02x -- $362.1M -$46.5M BTMDBiote1.06x 23.50x $51.4M $10.7M
-
Which has Higher Returns PIII or CCEL?
Cryo-Cell International has a net margin of -12.84% compared to P3 Health Partners's net margin of 8.15%. P3 Health Partners's return on equity of -26.35% beat Cryo-Cell International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M CCELCryo-Cell International74.83% $0.08 $2M -
What do Analysts Say About PIII or CCEL?
P3 Health Partners has a consensus price target of --, signalling upside risk potential of 228.95%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 14.94%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners0 0 0 CCELCryo-Cell International0 0 0 -
Is PIII or CCEL More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.
-
Which is a Better Dividend Stock PIII or CCEL?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.19% to investors and pays a quarterly dividend of $0.25 per share. P3 Health Partners pays -- of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or CCEL?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Cryo-Cell International quarterly revenues of $8M. P3 Health Partners's net income of -$46.5M is lower than Cryo-Cell International's net income of $655.8K. Notably, P3 Health Partners's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 2.03x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.02x -- $362.1M -$46.5M CCELCryo-Cell International2.03x -- $8M $655.8K
-
Which has Higher Returns PIII or OMCL?
Omnicell has a net margin of -12.84% compared to P3 Health Partners's net margin of 3.06%. P3 Health Partners's return on equity of -26.35% beat Omnicell's return on equity of -1.47%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M OMCLOmnicell43.29% $0.19 $1.8B -
What do Analysts Say About PIII or OMCL?
P3 Health Partners has a consensus price target of --, signalling upside risk potential of 228.95%. On the other hand Omnicell has an analysts' consensus of -- which suggests that it could grow by 25.77%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners0 0 0 OMCLOmnicell0 0 0 -
Is PIII or OMCL More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.577%.
-
Which is a Better Dividend Stock PIII or OMCL?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or OMCL?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Omnicell quarterly revenues of $282.4M. P3 Health Partners's net income of -$46.5M is lower than Omnicell's net income of $8.6M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Omnicell's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.94x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.02x -- $362.1M -$46.5M OMCLOmnicell1.94x -- $282.4M $8.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
